Browse Category

Stock Market 2 June 2026 - 3 June 2026

Abivax Shares Drop After Trial Win and Cancer Cases Raise Concerns

Abivax Shares Drop After Trial Win and Cancer Cases Raise Concerns

Abivax shares dropped hard Tuesday, despite positive late-stage trial results for its obefazimod drug. Investors focused on reported cancer and dysplasia cases in patients on the higher dose. The stock traded at 63.10 euros on Euronext Paris, well below Monday’s closing price of 111.80 euros, after touching 62.80 euros earlier. Over in the U.S., its Nasdaq ADRs were last at $72.86, down some 44% late in the session.
Dow, S&P inch up as AI surge faces $80 billion hurdle

Dow, S&P inch up as AI surge faces $80 billion hurdle

U.S. stocks finished Tuesday little changed. The Dow picked up 149.01 points, or 0.29%, to 51,227.89. The S&P 500 was up 4.85 points, or 0.06%, at 7,604.81. The Nasdaq Composite slipped 13.96 points, or 0.05%, closing at 27,072.85. Buyers stuck with AI names, while companies with high spending needs and Middle East risk got less support. Tim Ghriskey, senior portfolio strategist at Ingalls & Snyder, said it was “a mixed market today.”
Grab Stock Barely Moves. Its Bank Bet Is the Real Test Now

Grab Stock Barely Moves. Its Bank Bet Is the Real Test Now

Grab Holdings edged lower in Nasdaq trading on Tuesday, a muted move that left the Singapore-based superapp’s shares pinned near recent lows while investors weighed profit gains against the cost of its next leg of growth. The stock was recently at $3.60, down 0.3%, after trading between $3.59 and $3.66; volume stood at about 30.7 million shares and the company’s market value was about $14.2 billion.
AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 STRONG BUY

Xylem

NYSE: XYL 94 / 100
#2 BUY

AerCap

NYSE: AER 92 / 100
#3 BUY ON WEAKNESS

Visa

NYSE: V 89 / 100
#4 BUY IN TRANCHES

Lennox

NYSE: LII 87 / 100
#5 ACCUMULATE

UPS

NYSE: UPS 84 / 100
View full portfolio
Editorial model selection. Not personalised advice.